126 related articles for article (PubMed ID: 38701619)
1. The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ.
Li X; Hernandez I; Koyuncu S; Kis B; Häggblad M; Lidemalm L; Abbas AA; Bendegúz S; Göblös A; Brautigam L; Lucas JJ; Carreras-Puigvert J; Hühn D; Pircs K; Vilchez D; Fernandez-Capetillo O
EBioMedicine; 2024 May; 103():105124. PubMed ID: 38701619
[TBL] [Abstract][Full Text] [Related]
2. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
[TBL] [Abstract][Full Text] [Related]
3. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
Chiang MC; Chern Y; Huang RN
Neurobiol Dis; 2012 Jan; 45(1):322-8. PubMed ID: 21907283
[TBL] [Abstract][Full Text] [Related]
4. The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease.
Chiang MC; Chern Y; Juo CG
Biochim Biophys Acta; 2011 Sep; 1812(9):1111-20. PubMed ID: 21651979
[TBL] [Abstract][Full Text] [Related]
5. Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.
Chen M; Wolynes PG
Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4406-4411. PubMed ID: 28400517
[TBL] [Abstract][Full Text] [Related]
6. Exploding the Repeat Length Paradigm while Exploring Amyloid Toxicity in Huntington's Disease.
Wetzel R
Acc Chem Res; 2020 Oct; 53(10):2347-2357. PubMed ID: 32975927
[TBL] [Abstract][Full Text] [Related]
7. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma.
Chiang MC; Chen CM; Lee MR; Chen HW; Chen HM; Wu YS; Hung CH; Kang JJ; Chang CP; Chang C; Wu YR; Tsai YS; Chern Y
Hum Mol Genet; 2010 Oct; 19(20):4043-58. PubMed ID: 20668093
[TBL] [Abstract][Full Text] [Related]
8. Mn(II) Quinoline Complex (4QMn) Restores Proteostasis and Reduces Toxicity in Experimental Models of Huntington's Disease.
Merino M; Sequedo MD; Sánchez-Sánchez AV; Clares MP; García-España E; Vázquez-Manrique RP; Mullor JL
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012207
[TBL] [Abstract][Full Text] [Related]
9. A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis.
Lee YH; Tsai YS; Chang CC; Ho CC; Shih HM; Chen HM; Lai HL; Lee CW; Lee YC; Liao YC; Yang UC; Cheng TH; Chern Y; Soong BW
Mov Disord; 2022 Apr; 37(4):767-777. PubMed ID: 34951052
[TBL] [Abstract][Full Text] [Related]
10. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin.
Wang H; Lim PJ; Yin C; Rieckher M; Vogel BE; Monteiro MJ
Hum Mol Genet; 2006 Mar; 15(6):1025-41. PubMed ID: 16461334
[TBL] [Abstract][Full Text] [Related]
11. Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.
Nadal X; Del Río C; Casano S; Palomares B; Ferreiro-Vera C; Navarrete C; Sánchez-Carnerero C; Cantarero I; Bellido ML; Meyer S; Morello G; Appendino G; Muñoz E
Br J Pharmacol; 2017 Dec; 174(23):4263-4276. PubMed ID: 28853159
[TBL] [Abstract][Full Text] [Related]
12. TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models.
Hegde RN; Chiki A; Petricca L; Martufi P; Arbez N; Mouchiroud L; Auwerx J; Landles C; Bates GP; Singh-Bains MK; Dragunow M; Curtis MA; Faull RL; Ross CA; Caricasole A; Lashuel HA
EMBO J; 2020 Sep; 39(17):e104671. PubMed ID: 32757223
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of soluble and aggregating polyQ proteins on cytotoxicity and type-1 myosin-dependent endocytosis in yeast.
Berglund LL; Hao X; Liu B; Grantham J; Nyström T
Sci Rep; 2017 Sep; 7(1):11328. PubMed ID: 28900136
[TBL] [Abstract][Full Text] [Related]
15. Pathological polyQ expansion does not alter the conformation of the Huntingtin-HAP40 complex.
Huang B; Guo Q; Niedermeier ML; Cheng J; Engler T; Maurer M; Pautsch A; Baumeister W; Stengel F; Kochanek S; Fernández-Busnadiego R
Structure; 2021 Aug; 29(8):804-809.e5. PubMed ID: 33909994
[TBL] [Abstract][Full Text] [Related]
16. The polyglutamine domain is the primary driver of seeding in huntingtin aggregation.
Skeens A; Siriwardhana C; Massinople SE; Wunder MM; Ellis ZL; Keith KM; Girman T; Frey SL; Legleiter J
PLoS One; 2024; 19(3):e0298323. PubMed ID: 38483973
[TBL] [Abstract][Full Text] [Related]
17. Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.
Chandra A; Sharma A; Calingasan NY; White JM; Shurubor Y; Yang XW; Beal MF; Johri A
Hum Mol Genet; 2016 Jun; 25(11):2269-2282. PubMed ID: 27008868
[TBL] [Abstract][Full Text] [Related]
18. Zebrafish an experimental model of Huntington's disease: molecular aspects, therapeutic targets and current challenges.
Kumar V; Singh C; Singh A
Mol Biol Rep; 2021 Dec; 48(12):8181-8194. PubMed ID: 34665402
[TBL] [Abstract][Full Text] [Related]
19. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.
Hathorn T; Snyder-Keller A; Messer A
Neurobiol Dis; 2011 Jan; 41(1):43-50. PubMed ID: 20736066
[TBL] [Abstract][Full Text] [Related]
20. G3BP1-dependent mechanism suppressing protein aggregation in Huntington's models and its demise upon stress granule assembly.
Gutiérrez-Garcia R; Koyuncu S; Hommen F; Bilican S; Lee HJ; Fatima A; Vilchez D
Hum Mol Genet; 2023 May; 32(10):1607-1621. PubMed ID: 36611004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
